Short Interest in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Grows By 271.7%

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totalling 17,100 shares, a growth of 271.7% from the August 15th total of 4,600 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average daily trading volume, of 435,500 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Titan Pharmaceuticals in a research note on Friday, September 6th. They set a “sell” rating on the stock.

Titan Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ TTNP traded down $0.10 during midday trading on Thursday, reaching $5.53. 19,300 shares of the company traded hands, compared to its average volume of 182,667. The stock’s 50-day simple moving average is $5.83 and its 200-day simple moving average is $6.54. Titan Pharmaceuticals has a 12 month low of $4.24 and a 12 month high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.